HeraMED voluntary suspension and business update

HeraMED Limited (ASX: $HMD) has requested a voluntary suspension of its securities on the ASX as it undergoes a business restructure and seeks additional financing. The suspension is aimed at managing continuous disclosure obligations pending an announcement regarding changes in Directors and Management, business restructure, financial position, associated capital requirements, and proposed financing to fund ongoing operations.

Executive Commentary on Voluntary Suspension and Business Update

The voluntary suspension is a necessary step for HeraMED as we navigate through the process of securing additional funding and restructuring our business operations. We are actively engaged with third parties to secure the required funding, which is critical for our continued financial viability. The ongoing discussions and the nature of the changes to our Director and Management require careful consideration, and we believe that the voluntary suspension is essential to avoid any potential prejudice to our ability to complete these discussions and secure the necessary funding. We are working diligently to finalize these matters and intend to make the announcement by 29 April 2024. Further updates will be provided as the situation progresses.

Summary of HeraMED's Voluntary Suspension and Future Plans

HeraMED Limited (ASX: $HMD) has voluntarily suspended its securities to manage continuous disclosure obligations while it undergoes a business restructure and seeks additional financing. The company is actively engaged in discussions with third parties to secure the necessary funding, which is crucial for its financial viability. HeraMED aims to make an announcement regarding changes in Directors and Management, business restructure, financial position, associated capital requirements, and proposed financing by 29 April 2024. The company is committed to providing further updates as the situation develops.